Previous 10 | Next 10 |
Relay Therapeutics (NASDAQ:RLAY) will forge ahead with a single arm trial design for RLY-4008 for cholangiocarcinoma ("CCA"), also known as bile duct cancer. The company said it will examine FGFRi-naïve FGFR2-fusion CCA at 70 mg once daily in the hopes of an accelerated approval in a mid...
End-of-phase 1 meeting with the U.S. Food and Drug Administration (FDA) resulted in alignment on the design of a single arm trial for pan-FGFR (FGFRi) treatment-naïve FGFR2-fusion cholangiocarcinoma (CCA) to potentially support accelerated approval Interim data from the onc...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
CAMBRIDGE, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced registration is open fo...
Relay Therapeutics press release (NASDAQ:RLAY): Q1 GAAP EPS of -$0.57 beats by $0.05. Revenue of $0.42M (-55.8% Y/Y). As of March 31, 2022, cash, cash equivalents and investments totaled approximately $898 million compared to $958 million as of December 31, 2021. For further details see: ...
Initiated the fulvestrant combination arm of the first-in-human trial for RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor, and continued to enroll patients in the single agent arm Continued to enroll expansion cohorts for RLY-4008, a potent, selec...
CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10, 2022, at 3:20 p.m. PT in Las Vegas, NV. The fireside chat will be we...
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report first quarter 2022 fin...
Relay Therapeutics press release (NASDAQ:RLAY): FY GAAP EPS of -$3.82. Revenue of $3.03M. For further details see: Relay Therapeutics GAAP EPS of -$3.82, revenue of $3.03M
Announced RLY-4008 interim clinical data that suggest it is the first investigational therapy that selectively binds to FGFR2 and avoids off-isoform toxicities in the treatment of patients with FGFR2-altered tumors Shared preclinical data for RLY-2608, the first known allosteric...
News, Short Squeeze, Breakout and More Instantly...
Relay Therapeutics Inc. Company Name:
RLAY Stock Symbol:
NASDAQ Market:
Relay Therapeutics Inc. Website:
2024-06-14 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and is expected to fund operations into second half of 2026 Relay T...
CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced a clinical trial collabor...